Dr. A. Douglas Kinghorn leads $7 million NCI grant renewal for cancer drug discovery research

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the Ohio State College of Pharmacy have been awarded a five-year, $7 million competitive Program Project Grant (PPG) renewal from the National Cancer Institute (NCI).

The grant renewal extends through 2030 and is led by principal investigator A. Douglas Kinghorn, PhD, DSc, professor and Jack L. Beal Chair of the Division of Medicinal Chemistry and Pharmacognosy at the College of Pharmacy. He is also a member of the OSUCCC – James Molecular Carcinogenesis and Chemoprevention Program.

This renewal will continue to support the longest funded project at the college and is the only P01 grant supporting research in the college.

This multidisciplinary project grant represents the only PPG funded by the NCI in the nation led by a pharmacy investigator and will allow teams at Ohio State, the University of Illinois – Chicago and University of North Carolina – Greensboro to continue investigating potential anticancer drug leads based on compounds from tropical plants, coastal lichens, cultured cyanobacteria and filamentous fungi.